Cue Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
Cue Biopharma has a total shareholder equity of $25.4M and total debt of $5.3M, which brings its debt-to-equity ratio to 20.9%. Its total assets and total liabilities are $44.8M and $19.4M respectively.
Key information
20.9%
Debt to equity ratio
US$5.29m
Debt
| Interest coverage ratio | n/a |
| Cash | US$32.42m |
| Equity | US$25.37m |
| Total liabilities | US$19.44m |
| Total assets | US$44.81m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1UC's short term assets ($37.3M) exceed its short term liabilities ($16.8M).
Long Term Liabilities: 1UC's short term assets ($37.3M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: 1UC has more cash than its total debt.
Reducing Debt: 1UC's debt to equity ratio has increased from 0% to 20.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1UC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 1UC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.1% each year